GHRP-6 vs Ipamorelin

GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that functions as a potent ghrelin receptor (GHS-R1a) agonist, stimulating the anterior pituitary to release growth hormone in a pulsatile manner. Its mechanism involves both direct pituitary stimulation and hypothalamic amplification through GHRH neurons, producing robust GH elevations that mimic natural secretory patterns. Research published in the Journal of Endocrinology demonstrated that GHRP-6 administration in animal models produced significant GH release within 15-30 minutes, with peak levels 5-10 times above baseline. Studies by Bowers et al. (1991) were among the first to characterize its GH-releasing potency. Notably, research in Neuroscience Letters has indicated neuroprotective properties in ischemic brain injury models, where GHRP-6 reduced infarct volume and improved neurological outcomes through anti-apoptotic pathways. Compared to other GH secretagogues like Ipamorelin and GHRP-2, GHRP-6 produces the strongest appetite-stimulating effect due to its ghrelin-mimetic activity. It also raises cortisol and prolactin to a greater degree than Ipamorelin, making it less selective but more potent in overall GH output. GHRP-2 shares similar potency but with slightly reduced hunger effects. For storage, lyophilized GHRP-6 should be kept at -20C for long-term preservation. Once reconstituted with bacteriostatic water, store at 2-8C and use within 4 weeks. This peptide is widely studied by endocrinologists, neuroscientists investigating ischemia-reperfusion injury, and researchers examining growth hormone physiology and appetite regulation pathways.

Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor). Its mechanism involves binding the ghrelin receptor on anterior pituitary somatotrophs to trigger calcium influx and GH granule exocytosis. What distinguishes ipamorelin from earlier ghrelin mimetics is its remarkable selectivity: clinical studies by Raun et al. (European Journal of Endocrinology, 1998) demonstrated that ipamorelin stimulates GH release in a dose-dependent manner without significantly affecting cortisol, prolactin, FSH, LH, or TSH levels, even at high doses. This selectivity profile makes it one of the cleanest GH secretagogues available for research. In bone metabolism research, Anderson et al. (Bone, 2001) showed that ipamorelin administration in ovariectomized rat models increased bone mineral content and bone formation markers, suggesting anabolic effects on skeletal tissue independent of IGF-1 elevation. The peptide has also been studied in post-operative recovery models, where it demonstrated prokinetic effects on gastric motility. Compared to GHRP-6 and GHRP-2, which also activate the ghrelin receptor but additionally stimulate appetite and affect cortisol/prolactin levels, ipamorelin provides a more isolated GH response. Compared to hexarelin, another GHRP, ipamorelin shows less desensitization with repeated dosing. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. Ipamorelin is investigated by endocrinology labs, bone metabolism research centers, orthopedic research departments, and gastrointestinal motility researchers.

Frequently Asked Questions